Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colorectal Neoplasms × trilaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 7 Triple Negative Breast Neoplasms 4 Neoplasm Metastasis 3 Breast Neoplasms 3 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 186 Fluorouracil 148 Leucovorin 132 Cetuximab 125 Irinotecan 113 Oxaliplatin 107 pembrolizumab 96 Capecitabine 81 IFL protocol 53 regorafenib 42 Panitumumab 42 Nivolumab 42 Folfox protocol 39 Gemcitabine 30 trifluridine tipiracil drug combination 27 Cisplatin 24 Carboplatin 24 atezolizumab 22 Paclitaxel 20 Drug Therapy 20 Pemetrexed 19 130-nm albumin-bound paclitaxel 17 Trastuzumab 14 encorafenib 13 Ipilimumab 13 HMPL-013 13 tislelizumab 12 Trifluridine 12 spartalizumab 11 Docetaxel 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡